Amycretin stands out for an unusual reason: it is one of the few high-efficacy obesity drugs being developed as both a weekly injection and a daily pill. Made by Novo Nordisk, it is an investigational molecule that activates two appetite pathways, GLP-1 and amylin, and it is not FDA approved or available by prescription, from TrimRx or anywhere else, as of mid-2026. In early trials it produced striking weight loss, up to about 22 to 24% in one injectable study. Here is what it is and where it stands.<\/p>\n
Most drugs in this space hit one or two receptors. Amycretin is a single molecule (a “unimolecular” agonist) that activates both GLP-1 receptors, which reduce hunger and slow gastric emptying (the mechanism behind semaglutide and tirzepatide), and amylin receptors, which signal fullness through the brainstem.<\/p>\n
That makes amycretin conceptually similar to CagriSema, which also targets GLP-1 and amylin, but with a key difference: CagriSema combines two separate drugs in one injection, while amycretin does both jobs with a single molecule. Targeting amylin alongside GLP-1 is part of why researchers describe a strong effect on food noise<\/a>, the constant mental chatter about eating.<\/p>\n Amycretin is being developed in two formats: a once-weekly subcutaneous injection and a once-daily oral tablet. A high-efficacy oral option would be notable, because most strong weight-loss drugs require injections. Peptide drugs are normally broken down in the digestive tract, so an oral version that still drives meaningful weight loss is a real engineering step.<\/p>\n In an early oral trial, amycretin produced about 13.1% weight loss at 12 weeks, which Novo Nordisk noted was roughly double what semaglutide achieved at the same point. In a separate injectable trial of 125 adults, weight loss reached up to about 22 to 24% over 36 weeks at the highest doses, and notably had not plateaued by the end, suggesting more loss might be possible with longer treatment. Both sets of results were published in The Lancet in 2025. A 2025 Phase 2 trial in people with type 2 diabetes added more data, showing both formulations produced weight loss and improved blood sugar.<\/p>\n On the strength of those results, Novo Nordisk announced it would advance both the oral and injectable versions of amycretin straight into Phase 3 development for weight management, and it is also pursuing a diabetes program. Phase 3 is the final stage before a company can apply for approval, and it typically takes a few years. Industry estimates put a potential approval and launch somewhere around 2028 to 2029, assuming the larger trials confirm the early findings.<\/p>\n Until then, amycretin is investigational. It cannot be prescribed or compounded, and it is only available through clinical trials. Any “amycretin” offered for sale online is not a legitimate, regulated medication, and research-grade peptides carry real risks because they lack quality, purity, and dosing oversight.<\/p>\n Consider a scenario where someone is excited about an oral drug with injection-level results. That excitement is reasonable, but amycretin is years away, and the early numbers come from small, short trials that may shift in larger studies. The drugs available today already produce substantial weight loss. Semaglutide<\/a> is an approved, well-studied option, and for people who want to avoid the wait (and the risks of unproven shortcuts<\/a>), starting an approved medication now is the practical move.<\/p>\nThe standout feature: a pill and a shot<\/h3>\n
What the early data shows<\/h3>\n
\n\n
\n \nFormulation<\/th>\n Trial length<\/th>\n Weight loss<\/th>\n<\/tr>\n<\/thead>\n \n Oral (pill)<\/td>\n 12 weeks<\/td>\n ~13.1% (vs ~1% placebo)<\/td>\n<\/tr>\n \n Subcutaneous (injection)<\/td>\n 36 weeks<\/td>\n up to ~22-24% (dose-dependent)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Where it stands now<\/h3>\n
What this means for you<\/h3>\n